Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jeong, Seong Hyun | - |
dc.contributor.author | Kim, Dae Young | - |
dc.contributor.author | Jang, Jun Ho | - |
dc.contributor.author | Mun, Yeung-Chul | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Park, Joon Seong | - |
dc.date.accessioned | 2021-09-04T04:30:04Z | - |
dc.date.available | 2021-09-04T04:30:04Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-01 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89946 | - |
dc.description.abstract | Micafungin, a clinically important echinocandin antifungal drug, needs to be investigated as empirical therapy in febrile neutropenia in comparison with azole compounds. A prospective randomized study was conducted to compare clinical outcomes between micafungin and intravenous itraconazole as an empirical therapy for febrile neutropenia in hematological malignancies. The antifungal drug (micafungin 100 mg or itraconazole 200 mg IV once daily) was given for high fever that was sustained despite the administration of appropriate antibiotics. Treatment success was determined by composite end points based on breakthrough invasive fungal infection (IFI), survival, premature discontinuation, defervescence, and treatment of baseline fungal infection. Duration of fever, hospital stay, and overall survival (OS) were studied. A total of 153 patients were randomized to receive micafungin or itraconazole. The overall success rate was 7.1 % point higher in the micafungin group (64.4 vs. 57.3%, p=0.404), satisfying the statistical criteria for the non-inferiority of micafungin. The duration of fever and hospital stay were significantly shorter in the micafungin group (6 vs. 7 days, p=0.014; 22 vs. 27 days, p=0.033, respectively). Grade 3 adverse events including hyperbilirubinemia (2 vs. 7), elevation of transaminase levels (2 vs. 4), electrolyte imbalance (1 vs. 2), atrial fibrillation (1 vs. 0), and anaphylaxis (1 vs. 0) occurred in 7 and 13 patients in the micafungin (10.4 %) and itraconazole (18.8 %) groups, respectively. Micafungin, when compared with itraconazole, had favorably comparable success rate and toxicity profiles on febrile neutropenia in patients with hematological malignancies. In addition, it showed superior effect on shortening the hospital stay. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | LIPOSOMAL AMPHOTERICIN-B | - |
dc.subject | ACUTE MYELOID-LEUKEMIA | - |
dc.subject | PERSISTENT FEVER | - |
dc.subject | HIGH-RISK | - |
dc.subject | EUROPEAN ORGANIZATION | - |
dc.subject | FUNGAL-INFECTIONS | - |
dc.subject | CANCER-PATIENTS | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | PROPHYLAXIS | - |
dc.subject | FLUCONAZOLE | - |
dc.title | Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.identifier.doi | 10.1007/s00277-015-2545-2 | - |
dc.identifier.scopusid | 2-s2.0-84955205774 | - |
dc.identifier.wosid | 000371604500020 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.95, no.2, pp.337 - 344 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 95 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 337 | - |
dc.citation.endPage | 344 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | LIPOSOMAL AMPHOTERICIN-B | - |
dc.subject.keywordPlus | ACUTE MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | PERSISTENT FEVER | - |
dc.subject.keywordPlus | HIGH-RISK | - |
dc.subject.keywordPlus | EUROPEAN ORGANIZATION | - |
dc.subject.keywordPlus | FUNGAL-INFECTIONS | - |
dc.subject.keywordPlus | CANCER-PATIENTS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | PROPHYLAXIS | - |
dc.subject.keywordPlus | FLUCONAZOLE | - |
dc.subject.keywordAuthor | Micafungin | - |
dc.subject.keywordAuthor | Empirical | - |
dc.subject.keywordAuthor | Febrile neutropenia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.